U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Xu, Yang ^a   Luo, Qiang ^a   Lin, Ting ^a   Zeng, Zhiping ^a   Wang, Guanghui ^a   Zeng, Dequan ^a   Ding, Rong ^a   Sun, Cuiling ^a   Zhang, Xiao Kun ^a,b   Chen, Haifeng ^a  

^a XIAMEN UNIVERSITY   (China)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLINE; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; S6 KINASE 1; U 12; UNCLASSIFIED DRUG; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; TARGET OF RAPAMYCIN KINASE; URSODEOXYCHOLIC ACID;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHEPATOMA ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINT; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; CYCLINS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; MALE; MICE; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; URSODEOXYCHOLIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84915750834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113479     Document Type: Article

References (39)

1. Herszenyi L, Tulassay Z (2010) Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258.
2. Aravalli RN, Cressman EN, Steer CJ (2013) Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 87: 227-247.
3. Nojiri S, Nakao H, Sugauchi F, Miyaki T, Senda K, et al. (2009) Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection. Hepatol Res 39: 21-30.
4. Pardi DS, Loftus EV, Jr., Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889-893.
5. Kappler M, Espach C, Schweiger-Kabesch A, Lang T, Hartl D, et al. (2012) Ursodeoxycholic acid therapy in cystic fibrosis liver disease - a retrospective long-term follow-up case-control study. Aliment Pharmacol Ther.
6. Sola S, Ma X, Castro RE, Kren BT, Steer CJ, et al. (2003) Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J Biol Chem 278: 48831-48838.
7. Amaral JD, Castro RE, Steer CJ, Rodrigues CM (2009) p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol Med 15: 531-541.
8. Amaral JD, Castro RE, Sola S, Steer CJ, Rodrigues CM (2007) p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem 282: 34250-34259.
9. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, et al. (2005) Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97: 846-853.
10. Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, et al. (2008) Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer 60: 389-400.
11. Asciutti S, Castellani D, Nardi E, Morelli O, Clementi M, et al. (2009) A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon. Anticancer Res 29: 4971-4979.
12. Fiorucci S, Antonelli E, Distrutti E, Mencarelli A, Farneti S, et al. (2004) Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol 143: 33-42.
13. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, et al. (2001) NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 98: 8897-8902.
14. Im EO, Choi YH, Paik KJ, Suh H, Jin Y, et al. (2001) Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett 163: 83-93.
15. Choi YH, Im EO, Suh H, Jin Y, Yoo YH, et al. (2003) Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett 199: 157-167.
16. Im E, Choi SH, Suh H, Choi YH, Yoo YH, et al. (2005) Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-kappaB-dependent process in human cervical carcinoma cells. Cancer Lett 229: 49-57.
17. Yang F, Huo X-s, Yuan S-x, Zhang L, Zhou W-p, et al. (2013) Repression of the Long Noncoding RNA-LET by Histone Deacetylase 3 Contributes to Hypoxia-Mediated Metastasis. Molecular Cell 49: 1083-1096.
18. Xu Y, Chiu JF, He QY, Chen F (2009) Tubeimoside-1 exerts cytotoxicity in HeLa cells through mitochondrial dysfunction and endoplasmic reticulum stress pathways. J Proteome Res 8: 1585-1593.
19. Li Y, Jin M, Shao S, Huang W, Yang F, et al. (2014) Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model. BMC Cancer 14: 329.
20. Chen T, Xu Y, Guo H, Liu Y, Hu P, et al. (2011) Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One 6: e20729.
21. Im E, Martinez JD (2004) Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 134: 483-486.
22. Paolini M, Pozzetti L, Montagnani M, Potenza G, Sabatini L, et al. (2002) Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. Hepatology 36: 305-314.
23. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, et al. (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18: 2625-2631.
24. Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, et al. (2012) Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 156: 205-212.
25. Aravalli RN, Cressman EN, Steer CJ (2012) Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol.
26. Milovic V, Teller IC, Faust D, Caspary WF, Stein J (2002) Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation. Eur J Clin Invest 32: 29-34.
27. Markiewicz E, Dechat T, Foisner R, Quinlan RA, Hutchison CJ (2002) Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. Mol Biol Cell 13: 4401-4413.
28. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, et al. (2009) Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50: 1121-1129.
29. Jiang BH, Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76.
30. Dennis PB, Pullen N, Kozma SC, Thomas G (1996) The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 16: 6242-6251.
31. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
32. Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, et al. (2008) In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78: 563-571.
33. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, et al. (2012) Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res.
34. Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232.
35. Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, et al. (2012) Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin. PLoS One 7: e49456.
36. Kudo M (2011) mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig Dis 29: 310-315.
37. Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6: e26343.
38. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T (1999) Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 59: 3581-3587.
39. Zhang HS, Postigo AA, Dean DC (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 97: 53-61.